Exploring the Inheritance and Innovation of Traditional Chinese Medicine from the Perspective of Registration

Abstract

Objective To study the inheritance and innovation of traditional Chinese medicine, and to offer an insight for the public. Methods Literature review, data retrieval and systematic analysis were used to elaborate and summarize the influence of changes in related classification and policy reform of traditional Chinese medicine (TCM) registration on its inheritance and innovation. The study was carried out in the context of the TCM registration related classification and policy reform and evolution on TCM inheritance and innovation. Results and Conclusion TCM registration plays an important role in the inheritance and innovation of TCM, which greatly influences on its inheritance and innovation. The reform of new registration classification respects the law of TCM research and development, reflecting the establishment of the review and approval system in line with the characteristics of TCM inheritance, which promotes the research and development of new drugs. The establishment of the review and approval system also accelerates the marketing transformation of new traditional Chinese medicine. TCM innovation should attach importance to clinical value orientation and improve the scientific connotation of TCM. Meanwhile, the advantage of China’s accession to ICH, PIC/S and other international drug certification organizations should be taken to speed up the construction of international mutual recognition of TCM standardization system, which can provide a broader path for the inheritance and innovation of TCM in the new era.

Keywords

traditional Chinese medicine registration / traditional Chinese medicine innovation / internationalization of Chinese medicine

References

[1] Huang Ju, Li Geng, Zhang Xiaoxiao, et al. Relevant thoughts on development of traditional Chinese medicine industry in new era[J]. China Journal of Chinese Materia Medica, 2022, 47 (17): 4799-4813.

[2] Huang Ming, Yang Fengwen, Zhang Junhua, et al. Inheritance, innovation and development of traditional Chinese medicine in new era call for scientific supervision[J]. China Journal of Chinese Materia Medica, 2023, 48 (1):1-4.

[3] State Administration for Market Regulation. Provisions for Drug Registration (Bureau Order No. 27)[EB/OL].(2020-01-22)[2022-12-28]. http://gkml.samr.gov.cn/nsjg/fgs/202003/t20200330_313670.html.

[4] Yu Xiang, Li Na. Content analysis and basic evaluation of the third revised version of China’s “Provisions for Drug Registration”[J]. Biotechnology Law Report, 2018, 37 (2): 79-85.

[5] Qu Liping, Tang Jianyuan, Zhang Lei, et al. Category of Chinese medicine registration: Historical evolution, current status, and problems[J]. China Journal of Chinese Materia Medica, 2022, 47 (2): 562-568.

[6] Wang Shuo, Meng Fanying, Zhou Yingtao. Study on the overseas registration and development of traditional Chinese medicine products under the background of “Belt and Road Initiative”[J]. World Chinese Medicine, 2021, 16 (9): 1497-1500.

[7] Therapeutic Goods Administration. Overview of the regulation of listed medicines and registered complementary medicines[EB/OL]. (2021-08-20)[2022-12-28]. https:www.tga.gov.au/.

[8] Wang Hainan. Reform of evaluation and approval system of traditional Chinese medicine and the registration classification[J]. China Journal of New Drugs, 2021, 30 (3): 193-196.

[9] National Medical Products Administration. Notice of the State Drug Administration on the Issuance of the “Classification of Chinese Medicine Registration and Reporting Information Requirements” (2020 No. 68)[EB/OL]. (2020-09-28)[2022-12-28]. https:www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200928164311143.html.

[10] National Medical Products Administration. The State Drug Administration approved the marketing of lung detoxification granules, dampness defeating granules and lung defeating granules[EB/OL]. (2021-03-02)[2022-12-28]. https:www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20210302190503177.html.

[11] Lin Zhijian, Wang Hainan. The opportunity and challenge for the pharmacists of traditional Chinese medicine in new drug development under the new regulatory policy[J]. China Journal of New Drugs, 2022, 31 (9): 832-835.

[12] Wang Jingcan, Wen Baoshu, Pu Jiaqi. Insights into changes to the priority review system from the perspective of the new “Provisions for Drug Registration” in China[J]. Chinese Pharmaceutical Journal, 2020, 55 (24): 2074-2077.

[13] General Office of the State Council. Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices[EB/OL]. (2017-10-09)[2022-12-28]. https:www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20171009164201907.html.

[14] Huang Zhe, Li Meichen, Shi Hui, et al. Research on regulatory science of new Chinese medicine based on concept of whole life cycle[J]. Chinese Traditional and Herbal Drugs, 2021, 52 (17): 5132-5138.

[15] Ai Yanling, Tang Jianyuan, Zhou Gang, et al. Thoughts on path of R&D and registration of innovative traditional Chinese medicine with synchronous transformation of “series prescriptions”[J]. China Journal of Chinese Materia Medica, 2022, 47 (4): 1120-1125.

[16] Tang Jianyuan. Thoughts and suggestions on registration and classification of traditional Chinese medicines[J]. China Journal of Chinese Materia Medica, 2020, 45 (16): 4004-4008.

[17] Ren Jie, Liang Jinyan, Wan Qianyun, et al. Thoughts on the inheritance and innovation of traditional Chinese medicine[J]. Lishizhen Medicine and Materia Medica Research, 2020, 31 (7): 1689-1691.

[18] Wang Qingbai, Liu Feifei. Management of drug registration under the new situation of drug administration[J]. Shandong Chemical Industry, 2018, 47 (18): 97-99.

[19] Guo Jianfei, Han Sheng, Chen Jing, et al. Construction of post competency evaluation index system for drug registration specialist[J]. China Pharmacy, 2021, 32 (9): 1045-1050.

[20] Liu Yuting. Analysis of the necessity and feasibility of establishing a pharmaceutical registrar level evaluation system[J]. Private Technology, 2018 (1): 135.

[21] Zhao Xiaoxia. Analysis of innovative drug category 1.2 in traditional Chinese medicine and considerations on quality control of extracts[J]. China Journal of Chinese Materia Medica, 2021, 46 (10): 2601-2606.

[22] Zhang Tiejun, Liu Changxiao. Ideas and strategies of new traditional Chinese medicine research and development under new situation[J]. Chinese Traditional and Herbal Drugs, 2021, 52 (1): 1-8.

[23] Wang Ping, Yang Sheng, Zhang Jianwu. Design and establishment of drug registration management system in the new era - New concepts, new contents and new requirements of the provisions for drug registration (2020) and its implementation progress[J]. China Food & Drug Administration Magazine, 2021 (6): 8-17.

[24] Zhang Tao. Analysis of the newly revised measures for drug registration administration[J]. Journal of North Pharmacy, 2020, 17 (8): 161-162.

[25] Zhou Yuehua. Consideration and practice on pharmaceutical research and evaluation of “patient-focused” new traditional Chinese medicine[J]. Chinese Traditional and Herbal Drugs, 2022, 53 (13): 3889-3896.

[26] Li Haona, Wang Siwang, Yue Zhihua, et al. Traditional Chinese herbal injection: Current status and future perspectives[J]. Fitoterapia, 2018, 129: 249-256.

[27] Qu Liping, Zeng Jie, Huang Q ianqian, et al. Enlightenments of the European herbal medicinal product regulation model to the administration of TCM in China[J]. Modernization of Traditional Chinese Medicine and Materia Medica - World Science and Technology, 2020, 22 (2): 434-440.

[28] Ge Wenxia, Qian Xincheng, Shao Rong. Enlightenment of the European Union’s traditional herbal medicine registration system to the simplified registration and monitoring system of Chinese classical formulas[J]. China Pharmacy, 2020, 31 (23): 2817-2821.